Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating

MT Newswires19:06 · Ratings

Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages

TipRanks13:45

Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's

Barron'sNov 23 10:30

Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC

Seeking AlphaNov 23 10:25

Replimune Climbs After Updates on Lead Drug

Seeking AlphaNov 22 21:31

Optimism Over Global Healthcare Sector Rises: Jefferies

Seeking AlphaNov 22 02:45